Directorio de personas
Luis Brieva Ruiz

Luis Brieva Ruiz

Grado: Doctor/a

973 705 367
lbrieva.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/C-3812-2011

Grupos

Publicaciones

  • Gonzalez-Mingot, C; Lopez-Ortega, R; Brieva-Ruiz, L

    The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2

    NEUROLOGICAL SCIENCES 43 5099-5101. .

    [doi:10.1007/s10072-022-06144-2]

  • Brieva, L; Estruch, BC; Merino, JAG; Meca-Lallana, V; Rio, J; Rodriguez-Antigueedad, A; Aguera, E; Ara, JR; Luque, AA; Garcia, CA; Blanco, Y; Castillo-Trivino, T; Costa-Frossard, L; Platas, MG; Pascual, LL; Llaneza-Gonzalez, M; Gines, MLM; Matias-Guiu, J; Meca-Lallana, JE; Bilbao, MM; Sempere, AP; Romero-Pinel, L; Saiz, A; Moral, E

    Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology

    Multiple Sclerosis and Related Disorders 63 -. .

    [doi:10.1016/j.msard.2022.103805]

  • Vermersch P; Brieva-Ruiz L; Fox RJ; Paul F; Ramio-Torrenta L; Schwab M; Moussy A; Mansfield C; Hermine O; Maciejowski M

    Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.

    Neurology-Neuroimmunology & Neuroinflammation 9 -. .

    [doi:10.1212/NXI.0000000000001148]

  • Sancho-Saldana, A; Gil Sánchez A; Quirant-Sanchez, B; Nogueras, L; Peralta, S; Solana, MJ; Gonzalez-Mingot, C; Gallego, Y; Quibus, L; Ramo-Tello, C; Presas-Rodriguez, S; Martinez-Caceres, E; Torres, P; Hervas, JV; Valls, J; Brieva, L

    Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies.

    Journal of Clinical Medicine 11 -. .

    [doi:10.3390/jcm11092509]

  • Fernández-Velasco JI; Monreal E; Kuhle J; Meca-Lallana V; Meca-Lallana J; Izquierdo G; Oreja-Guevara C; Gascón-Giménez F; Sainz de la Maza S; Walo-Delgado PE; Lapuente-Suanzes P; Maceski A; Rodríguez-Martín E; Roldán E; Villarrubia N; Saiz A; Blanco Y; Diaz-Pérez C; Valero-López G; Diaz-Diaz J; Aladro Y; Brieva L; Íñiguez C; González-Suárez I; Rodríguez de Antonio LA; García-Domínguez JM; Sabin J; Llufriu S; Masjuan J; Costa-Frossard L; Villar LM

    Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology.

    Frontiers in Immunology 13 842354-842354. .

    [doi:10.3389/fimmu.2022.842354]

  • de la Maza, SS; Maurino, J; Borges, M; Martín-Martínez, J; Sotoca, J; Alonso, A; Caminero, AB; Borrega, L; Sánchez-Menoyo, JL; Barrero-Hernández, FJ; Calles, C; Brieva, L; Blasco, MR; García-Soto, JD; del Campo-Amigo, M; Navarro-Cantó, L; Agüera, E; Garcés, M; Carmona, O; Gabaldón-Torres, L; Forero, L; Hervás, M; de Alda, LR; Gómez-Ballesteros, R; Castillo-Triviño, T

    Measuring productivity loss in early relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders 58 -. .

    [doi:10.1016/j.msard.2021.103398]

  • Ramo-Tello C; Blanco Y; Brieva L; Casanova B; Martínez-Cáceres E; Ontaneda D; Ramió-Torrentá L; Rovira À

    Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.

    Journal of Personalized Medicine 12 -. .

    [doi:10.3390/jpm12010006]

  • Granell-Geli, J; Izquierdo-Gracia, C; Selles-Rius, A; Teniente-Serra, A; Presas-Rodriguez, S; Mansilla, MJ; Brieva, L; Sotoca, J; Mane-Martinez, MA; Moral, E; Bragado, I; Goelz, S; Martinez-Caceres, E; Ramo-Tello, C

    Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab

    Journal of Personalized Medicine 11 -. .

    [doi:10.3390/jpm11121347]

  • Munoz-Lopetegi, A; Pujol, M; Gimenez, M; Gaig, C; Brieva, L; Santamaria, J

    Abnormal sleep behavior caused by hypoglycemia

    SLEEP MEDICINE 85 268-270. .

    [doi:10.1016/j.sleep.2021.07.029]

  • Meca-Lallana, J; Garcia-Merino, JA; Martinez-Yelamos, S; Vidal-Jordana, A; Costa, L; Eichau, S; Rovira À; Brieva, L; Aguera, E; Zarranz, ARA

    Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies.

    Neurodegenerative Disease Management 11 251-261. .

    [doi:10.2217/nmt-2020-0049]

  • Fernandez-Velasco, JI; Kuhle, J; Monreal, E; Meca-Lallana, V; Meca-Lallana, J; Izquierdo, G; Gascon-Gimenez, F; de la Maza, SS; Walo-Delgado, PE; Maceski, A; Rodriguez-Martin, E; Roldan, E; Villarrubia, N; Saiz, A; Blanco, Y; Sanchez, P; Carreon-Guarnizo, E; Aladro, Y; Brieva, L; Iniguez, C; Gonzalez-Suarez, I; de Antonio, LAR; Masjuan, J; Costa-Frossard, L; Villar, LM

    Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

    Neurology-Neuroimmunology & Neuroinflammation 8 -. .

    [doi:10.1212/NXI.0000000000000940]

  • Maurino J; Sotoca J; Sempere ÁP; Brieva L; López de Silanes C; Caminero AB; Terzaghi M; Gracia-Gil J; Saposnik G

    High-Efficacy Disease-Modifying Therapies in People with Relapsing-Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions.

    Patient-Patient Centered Outcomes Research 14 241-248. .

    [doi:10.1007/s40271-020-00454-3]

Proyectos

  • EMCOVID-19: Esclerosis Múltiple y COVID-19
  • "Registro de pacientes con esclerosis múltiple (EM) tratados con Natalizumab en España"
  • UTILIDAD DE LA REALIZACION DE SECUENCIAS DE DIFUSION Y LA DETERMINACION DE BIOMARCADORES EN EL PRONOSTICO DE LOS PACIENTES CON UN ATAQUE ISQUEMICO TRANSITORIO